Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Tapping the potential of fixed-dose combinations

Nature Reviews Drug Discovery volume 6, pages 513–514 (2007)Cite this article

Asthma

Competition in the US FDC asthma market is primed to increase in the near term. AstraZeneca is poised to launch Symbicort (budesonide/formoterol; $1.2 billion sales in 2006 outside the US), another ICS/LABA product, in mid-2007 in the US. In addition GSK is developing a follow-on ICS/LABA product “Super Advair”, which offers a once daily rather than twice daily administration benefit. Several other ICS/LABA FDC candidates are also in clinical trials with potential US launches in the 2010–2011 time frame (Table 1).

Table 1 Notable FDC candidates in clinical development and recent launches
Full size table

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global sales of fixed-dose-combination examples and each individual component.

References

  1. Frantz, S. The trouble with making combination drugs. Nature Rev. Drug Discov. 5, 881–882 (2006).

    Article  Google Scholar 

  2. National Institutes of Health. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute web site [online],; (1997).

  3. Nelson, H. S. et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunology 112, 29–36 (2003).

    Article  CAS  Google Scholar 

  4. Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. AIDSinfo web site [online], (2006).

  5. Berenson, A. Heart pill to be sold by itself. The New York Times (26 July 2006).

    Google Scholar 

  6. Schering–Plough. Press release: Schering–Plough and Merck to develop another new cholesterol lowering medicine. Schering–Plough web site [online] (26 March 2007).

Download references

Author information

Authors and Affiliations

  1. Tara M. Herrick and Ryan P. Million are at Trinity Partners, 100 Park Avenue, Suite 1600, New York 10017, USA.,

    Tara M. Herrick & Ryan P. Million

Authors
  1. Tara M. Herrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

DATABASES

Advair

Atripla

Caduet

Symbicort

Vytorin

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrick, T., Million, R. Tapping the potential of fixed-dose combinations. Nat Rev Drug Discov 6, 513–514 (2007). https://doi.org/10.1038/nrd2334

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2334

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing